NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

References

• Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 2020;15(2):288–293. doi:10.1016/j.jtho.2019.10.002.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094.
   PubMed Web of Science ®Google Scholar
• Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715–1722. doi:10.1093/annonc/mdv177.
   PubMed Web of Science ®Google Scholar
• Jiang T, Li X, Wang J, Su C, Han W, Zhao C, et al. Mutational landscape of cfDNA identifies distinct molecular features associated with therapeutic response to first-line platinum-based doublet chemotherapy in patients with advanced NSCLC. Theranostics. 2017;7(19):4753–4762. doi:10.7150/thno.21687.
   PubMed Web of Science ®Google Scholar
• Egyud M, Tejani M, Pennathur A, Luketich J, Sridhar P, Yamada E, et al. Detection of circulating tumor DNA in plasma: a potential biomarker for esophageal adenocarcinoma. Ann Thorac Surg. 2019;108(2):343–349. doi:10.1016/j.athoracsur.2019.04.004.
   PubMed Web of Science ®Google Scholar
• Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–1047. doi:10.15252/emmm.201404913.
   PubMed Web of Science ®Google Scholar
• Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717–721. doi:10.1001/jamaoncol.2017.5332.
   PubMed Web of Science ®Google Scholar
• Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nat Cancer. 2020;1(2):176–183. doi:10.1038/s43018-019-0011-0.
   PubMedGoogle Scholar
• Jiang T, Shi J, Dong Z, Hou L, Zhao C, Li X, et al. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. J Hematol Oncol. 2019;12(1):75. doi:10.1186/s13045-019-0762-1.
   PubMedGoogle Scholar
• Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–641. doi:10.1200/jco.2017.75.3384.
   PubMed Web of Science ®Google Scholar
• Goldberg ME, Gay LM, Fabrizio D, Frampton GM, Elvin JA, Ross JS, et al. Abstract 1775: The interaction of PD-L1, TMB, and genomic alterations in NSCLC. Cancer Research. 2017;77(13_Supplement):1775–1775. doi:10.1158/1538-7445.AM2017-1775.
   PubMedGoogle Scholar
• Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, Kulasinghe A. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41(3):1474–1498. doi:10.1002/med.21765.
   PubMed Web of Science ®Google Scholar
• Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448. doi:10.1038/s41591-018-0134-3.
   PubMed Web of Science ®Google Scholar
• Kim E, Velcheti V, Mekhail T, Leal T, Dowell J, Tsai M, et al. LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology. 2018;29:viii744. doi:10.1093/annonc/mdy424.067.
   Web of Science ®Google Scholar
• Velcheti V, Kim E, Mekhail T, Dakhil C, Stella P, Shen X, et al. Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. JCO. 2018;36(15_suppl):12001–12001. doi:10.1200/JCO.2018.36.15_suppl.12001.
   Web of Science ®Google Scholar
• Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol. 2019;5(5):696–702. doi:10.1001/jamaoncol.2018.7098.
   PubMed Web of Science ®Google Scholar
• Xie Z, Liu L, Lin X, Xie X, Gu Y, Liu M, et al. A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung. Mod Pathol. 2020;33(4):626–638. doi:10.1038/s41379-019-0391-9.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/s1470-2045(20)30445-9.
   PubMed Web of Science ®Google Scholar
• Aggarwal C, Thompson JC, Chien AL, Quinn KJ, Hwang WT, Black TA, et al. Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer. Clin Cancer Res. 2020;26(10):2354–2361. doi:10.1158/1078-0432.Ccr-19-3663.
   PubMed Web of Science ®Google Scholar
• Wen X, Bin H, Lei Y, Jing Z, Li L, Peisu S, et al. Mutation concordance of matched tissue sample and blood sample: A result of 456 lung cancer patients. JCO. 2019;37(15_suppl):e20049–e20049. doi:10.1200/JCO.2019.37.15_suppl.e20049.
   Google Scholar
• Jiang J, Adams HP, Yao L, Yaung S, Lal P, Balasubramanyam A, et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I-IV non-small cell lung cancer. J Mol Diagn. 2020;22(2):228–235. doi:10.1016/j.jmoldx.2019.10.013.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016;7(40):65364–65373. doi:10.18632/oncotarget.11692.
   PubMed Web of Science ®Google Scholar
• Mardinian K, Okamura R, Kato S, Kurzrock R. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2020;146(2):566–576. doi:10.1002/ijc.32510.
   PubMed Web of Science ®Google Scholar
• Kulasinghe ’, O'Leary C, Monkman J, Bharti V, Irwin D, Dutta S, et al. The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer. 2021;160:73–77. doi:10.1016/j.lungcan.2021.08.005.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, et al. Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Mol Cancer Ther. 2017;16(7):1412–1420. doi:10.1158/1535-7163.Mct-17-0061.
   PubMed Web of Science ®Google Scholar
• Peng H, Lu L, Zhou Z, Liu J, Zhang D, Nan K, et al. CNV detection from circulating tumor DNA in late stage non-small cell lung cancer patients. Genes (Basel). 2019;10(11):926. doi:10.3390/genes10110926.
   PubMed Web of Science ®Google Scholar
• Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23(5):700–713.e6. e706. doi:10.1016/j.stem.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Zajkowicz A, Butkiewicz D, Drosik A, Giglok M, Suwiński R, Rusin M. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. Br J Cancer. 2015;112(6):1114–1120. doi:10.1038/bjc.2015.79.
   PubMed Web of Science ®Google Scholar
• Otto JE, Kadoch C. A two-faced mSWI/SNF subunit: dual roles for ARID1A in tumor suppression and oncogenicity in the liver. Cancer Cell. 2017;32(5):542–543. doi:10.1016/j.ccell.2017.10.014.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13(1):34. doi:10.1186/s40246-019-0220-8.
   PubMed Web of Science ®Google Scholar
• Yasui K, Kondou R, Iizuka A, Miyata H, Tanaka E, Ashizawa T, et al. Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients. J Radiat Res. 2020;61(5):766–775. doi:10.1093/jrr/rraa041.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–3421. doi:10.1172/jci80008.
   PubMed Web of Science ®Google Scholar
• Giordano FA, Veldwijk MR, Herskind C, Wenz F. Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. Strahlenther Onkol. 2018;194(10):873–875. doi:10.1007/s00066-018-1341-z.
   PubMed Web of Science ®Google Scholar
• Jonna S, Vanderwalde AM, Nieva JJ, Poorman KA, Saul M, von Buttlar X, et al. Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC. JCO. 2019;37(15_suppl):2627–2627. doi:10.1200/JCO.2019.37.15_suppl.2627.
   Web of Science ®Google Scholar
• Singh A, Mencia-Trinchant N, Griffiths EA, Altahan A, Swaminathan M, Gupta M, et al. Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy. JCO Precis Oncol. 2022;6:e2100309. doi:10.1200/po.21.00309.
   PubMed Web of Science ®Google Scholar
• Tahri S, Mouhieddine TH, Redd R, Lampe L, Nilsson KI, El-Khoury H, et al. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022;6(7):2230–2235. doi:10.1182/bloodadvances.2021004926.
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Torok JA, Hatch AJ, Xanthopoulos EP, Lafata K, Jacobs C, et al. Dynamic changes in circulating tumor DNA during chemoradiation for locally advanced lung cancer. Adv Radiat Oncol. 2019;4(4):748–752. doi:10.1016/j.adro.2019.05.004.
   PubMedGoogle Scholar
• Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, et al. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist. 2019;24(6):820–828. doi:10.1634/theoncologist.2018-0433.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872–1880. doi:10.1158/1078-0432.Ccr-17-1341.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi:10.1038/nature22364.
   PubMed Web of Science ®Google Scholar
• Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han C-T, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180. doi:10.1186/s40425-019-0659-0.
   PubMedGoogle Scholar
• Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial. J Thorac Oncol. 2022;17(2):289–308. doi:10.1016/j.jtho.2021.09.010.
   PubMed Web of Science ®Google Scholar
• Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466–477. doi:10.1016/j.annonc.2021.01.074.
   PubMed Web of Science ®Google Scholar
• Cui S, Cheng Z, Qin W, Jiang L. Exosomes as a liquid biopsy for lung cancer. Lung Cancer. 2018;116:46–54. doi:10.1016/j.lungcan.2017.12.012.
   PubMed Web of Science ®Google Scholar
• Kapeleris J, Ebrahimi Warkiani M, Kulasinghe A, Vela I, Kenny L, Ladwa R, et al. Clinical applications of circulating tumour cells and circulating tumour dna in non-small cell lung cancer-an update. Front Oncol. 2022;12:859152. doi:10.3389/fonc.2022.859152.
   PubMedGoogle Scholar
• Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, et al. Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1/PD-L1 inhibitors. Cancers (Basel). 2019;11(6):835. doi:10.3390/cancers11060835.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, et al. Tumor mutational burden and PTEN alterations as molecular correlates of response to pd-1/l1 blockade in metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26(11):2565–2572. doi:10.1158/1078-0432.Ccr-19-3507.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim B, Kang SY, Heo YJ, Park SH, Kim ST, et al. Tumor mutational burden determined by panel sequencing predicts survival after immunotherapy in patients with advanced gastric cancer. Front Oncol. 2020;10:314. doi:10.3389/fonc.2020.00314.
   PubMed Web of Science ®Google Scholar
• Li W, Matakidou A, Ghazoui Z, Si H, Wildsmith S, Morsli N, et al. Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies. JCO. 2020;38(15_suppl):6548–6548. doi:10.1200/JCO.2020.38.15_suppl.6548.
   Web of Science ®Google Scholar